Concord Biotech Limited (NSE:CONCORDBIO)

Concord Biotech Revenue

In the fiscal year ending March 31, 2026, Concord Biotech had annual revenue of 10.55B INR, down -12.10%. Concord Biotech had revenue of 3.26B in the quarter ending March 31, 2026, a decrease of -24.15%.

• Revenue: 10.55B
• Revenue Growth: -12.10%
• P/S Ratio: 11.57
• Revenue / Employee: 6.71M
• Employees: 1,571
• Market Cap: 122.00B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	10.55B	-1.45B	-12.10%
Mar 31, 2025	12.00B	1.83B	18.01%
Mar 31, 2024	10.17B	1.64B	19.20%
Mar 31, 2023	8.53B	1.40B	19.67%
Mar 31, 2022	7.13B	959.91M	15.56%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 3, 2026

Data Sources Report a data error